- At a meeting today with analysts, Johnson & Johnson’s Janssen Pharmaceuticals announced plans for regulatory approval of more than 10 new drugs between 2015 and 2019, each with the potential to generate at least $1B in sales, in addition to over 40 line extensions of existing and new medicines. It projects top-line growth above the industry average through 2019.
- Janssen’s product portfolio is focused on five core therapeutic areas: Immunology, Infectious Diseases & Vaccines, Neuroscience, Cardiovascular & Metabolism and Oncology. It has launched 14 new products since 2009, seven of which will achieve blockbuster status (sales of $1B+) this year.
- Late stage products include daratumumab for multiple myeloma; sirukumab for rheumatoid arthritis; guselkumab for psoriasis; JNJ-927 (ARN0509) for pre-metastatic prostate cancer; imetelstat for myelofibrosis; JNJ-493 for urothelial cancer; esketamine for treatment-resistant depression and AL-8176 for hepatitis C.
- In February of this year, Janssen announced the launch of three new research platforms focused on disease prevention, disease intervention and the microbiome, with the intent to potentially change the way diseases are managed.
- According the IMS Health, the global pharmaceutical market reached $1T last year with 40% of the growth coming from specialty drugs. It is expected to grow ~3% per annum through 2019.
